Journal
ONCOLOGY REPORTS
Volume 31, Issue 4, Pages 1509-1516Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2014.3036
Keywords
biomarker; cancer; prognosis; miR-29; epithelial-mesenchymal transition; diagnosis; apoptosis
Categories
Funding
- National Natural Science Foundation of China [NSFC30801417]
- Natural Science Foundation of Jiangsu Province [BK2009010]
- Doctoral Fund of the Ministry of Education of China [RFDP200802841004]
- Science Fund of the Ministry of Health of China [LW201008]
- Medical Science and Technology Development Foundation, Nanjing Department of Health [ZKX12011]
Ask authors/readers for more resources
microRNAs (miRNAs) are non-coding RNAs which have the capacity to regulate gene expression at the post-transcriptional level, and have emerging as key factors involved in cancer at all stages ranging from initiation to metastasis. In the present review, we summmarize the diverse roles of the microRNA-29 (miR-29) family in cancer. First, we present a concise introduction to the miR-29 family and the expression profile of miR-29 in various cancer types. We next highlight the upstream regulatory pathway of miR-29 and describe the relationship between miR-29 and cancer in detail. As a tumor suppressor, miR-29 restrains cancer progression by promoting tumor cell apoptosis, by suppressing DNA methylation of tumor-suppressor genes, by reducing proliferation of tumors and by increasing chemosensitivity. However, as a tumor promoter, miR-29 mediates epithelial-mesenchymal transition (EMT) and promotes metastasis in breast cancer and colon cancer. Finally, we suggest that miR-29 represents a novel diagnostic and prognostic biomarker or a therapeutic target for cancer. Our review highlights the diverse relationship between miR-29 and cancer (particularly digestive system neoplasms). Further research of miR-29 in cancer is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available